Berotralstat
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Donidalorsen (Dawnzera) for prevention of hereditary angioedema attacks.
Journal: The Medical letter on drugs and therapeutics
Published: January 08, 2026
Garadacimab (Andembry) for hereditary angioedema prophylaxis.
Journal: The Medical letter on drugs and therapeutics
Published: November 05, 2025
Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile.
Journal: Medicina (Kaunas, Lithuania)
Published: September 18, 2025
Utility of fluorescamine for spectrofluorimetric quantitation of berotralstat hydrochloride in spiked human plasma and content uniformity test and evaluation of method greenness.
Journal: Scientific reports
Published: September 18, 2025
Berotralstat, the first oral prophylaxis for hereditary angioedema in children aged 2 to 12 years: The kids are alright!
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: July 31, 2025
Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives.
Journal: Expert opinion on pharmacotherapy
Published: June 24, 2025
Comment on: "A national survey of four decades of hereditary angioedema prophylaxis" - The emerging role of Garadacimab.
Journal: Clinical immunology (Orlando, Fla.)
Published: June 19, 2025
Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years: APeX-P interim results.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: June 03, 2025
Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: May 30, 2025
Last Updated: 02/24/2026